V Craig Jordan

List of Publications by Year
in descending order

186	15,250	31976 53	17592 121
papers	citations	h-index	g-index

189	189	189	9916
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women. JAMA - Journal of the American Medical Association, 1999, 281, 2189.	7.4	1,661
2	Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2006, 295, 2727.	7.4	1,499
3	Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer. New England Journal of Medicine, 1992, 326, 852-856.	27.0	1,089
4	Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery, 2003, 2, 205-213.	46.4	676
5	Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial. Breast Cancer Research and Treatment, 2001, 65, 125-134.	2.5	629
6	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research, 2010, 3, 696-706.	1.5	560
7	Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions. Journal of Medicinal Chemistry, 2003, 46, 883-908.	6.4	396
8	Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents. Journal of Medicinal Chemistry, 2003, 46, 1081-1111.	6.4	392
9	Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Research and Treatment, 1987, 10, 31-35.	2.5	331
10	The estrogen receptor: a model for molecular medicine. Clinical Cancer Research, 2003, 9, 1980-9.	7.0	317
11	Selective estrogen receptor modulation. Cancer Cell, 2004, 5, 207-213.	16.8	307
12	The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice. Current Clinical Pharmacology, 2013, 8, 135-155.	0.6	297
13	Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 5815-5824.	1.6	285
14	Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 2007, 72, 7-25.	1.8	282
15	Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology, 2006, 147, S269-S276.	5.4	254
16	A current view of tamoxifen for the treatment and prevention of breast cancer. British Journal of Pharmacology, 1993, 110, 507-517.	5.4	252
17	Intrinsic Mechanism of Estradiol-Induced Apoptosis in Breast Cancer Cells Resistant to Estrogen Deprivation. Journal of the National Cancer Institute, 2005, 97, 1746-1759.	6.3	229
18	Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?. Breast Cancer Research, 2009, 11, 206.	5.0	208

#	Article	IF	Citations
19	Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Reviews Cancer, 2007, 7, 46-53.	28.4	198
20	Tamoxifen: Catalyst for the change to targeted therapy. European Journal of Cancer, 2008, 44, 30-38.	2.8	174
21	Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18879-18886.	7.1	151
22	The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Research and Treatment, 1994, 31, 129-138.	2.5	144
23	Apoptotic Action of 17Â-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo. Journal of the National Cancer Institute, 2003, 95, 1586-1597.	6.3	140
24	Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocrine-Related Cancer, 2014, 21, R235-R246.	3.1	128
25	Paradoxical Action of Fulvestrant in Estradiol-Induced Regression of Tamoxifen-Stimulated Breast Cancer. Journal of the National Cancer Institute, 2003, 95, 1597-1608.	6.3	121
26	The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor Î± and Cyclin D1. Molecular Pharmacology, 2011, 80, 610-620.	2.3	113
27	Long-term tamoxifen adjuvant therapy in node-positive breast cancer: A metabolic and pilot clinical study. Breast Cancer Research and Treatment, 1984, 4, 297-302.	2.5	112
28	Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Research and Treatment, 1990, 15, 125-136.	2.5	112
29	The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocrine-Related Cancer, 2015, 22, R1-R31.	3.1	111
30	Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. European Journal of Cancer & Clinical Oncology, 1987, 23, 1935-1939.	0.7	110
31	Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. European Journal of Cancer & Clinical Oncology, 1990, 26, 883-888.	0.7	107
32	The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancerâ€"Survival or Death?. Journal of Clinical Oncology, 2008, 26, 3073-3082.	1.6	98
33	Investigation of the Mechanism of Tamoxifen-Stimulated Breast Tumor Growth With Nonisomerizable Analogues of Tamoxifen and Metabolites. Journal of the National Cancer Institute, 1993, 85, 806-812.	6.3	89
34	Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications. Breast Cancer Research and Treatment, 1983, 3, S73-S86.	2.5	88
35	Chemosuppression of Breast Cancer with Tamoxifen: Laboratory Evidence and Future Clinical Investigations. Cancer Investigation, 1988, 6, 589-595.	1.3	88
36	Molecular Mechanism of Action at Estrogen Receptor Î± of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen**This work was supported by NIH CA-56143 (to V.C.J.); Fundacl§ao Coordenacl§ao de Aperfeicl§oamento de Pessoal de Nivel Superior, (CAPES) Scholarship, Brazil (to R.D.); the U.S. Army Medical Research and Material Command Breast Cancer Research Program, DAMD17â€"96-16169 (to H.L.); the generosity of the Lynn Sage Breast Cancer Research Foundation of Northwestern Memorial Hospital; and the. Endocrinology, 2001, 142, 838-846.	2.8	84

#	Article	IF	Citations
37	Antiestrogenic Action of Raloxifene and Tamoxifen: Today and Tomorrow. Journal of the National Cancer Institute, 1998, 90, 967-971.	6.3	78
38	c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells. Cancer Research, 2013, 73, 4510-4520.	0.9	77
39	Inhibition of the Uterotropic Activity of Estrogens and Antiestrogens by the Short Acting Antiestrogen LY117018*. Endocrinology, 1983, 113, 463-468.	2.8	76
40	A Novel 80 kDa Human Estrogen Receptor Containing a Duplication of Exons 6 and 7. Nucleic Acids Research, 1996, 24, 962-969.	14.5	75
41	Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Research and Treatment, 1994, 31, 117-127.	2.5	68
42	Structure-Function Relationships of the Raloxifene-Estrogen Receptor-Î± Complex for Regulating Transforming Growth Factor-Î± Expression in Breast Cancer Cells. Journal of Biological Chemistry, 2002, 277, 9189-9198.	3.4	68
43	Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice. Journal of the National Cancer Institute, 2002, 94, 274-283.	6.3	65
44	Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. European Journal of Cancer & Clinical Oncology, 1989, 25, 57-63.	0.7	62
45	Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Hormone Molecular Biology and Clinical Investigation, 2012, 9, 143-163.	0.7	62
46	Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A â€œNewâ€•Biology of Estrogen-induced Apoptosis. Cancer Prevention Research, 2011, 4, 633-637.	1.5	59
47	Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Research, 2008, 10, R104.	5.0	58
48	Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Hormone Molecular Biology and Clinical Investigation, 2010, 2, 235-243.	0.7	58
49	Growth Stimulation and Differential Regulation of Transforming Growth Factor-Î²1 (TGFÎ²1), TGFÎ²2, and TGFÎ²3 Messenger RNA Levels by Norethindrone in MCF-7 Human Breast Cancer Cells. Molecular Endocrinology, 1991, 5, 1120-1128.	3.7	57
50	A Risk-Benefit Assessment of Tamoxifen Therapy. Drug Safety, 1993, 8, 381-397.	3.2	56
51	Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Research and Treatment, 1994, 31, 11-25.	2.5	55
52	Hormone Receptor Assays: Clinical Usefulness in the Management of Carcinoma of the Breast. CRC Critical Reviews in Clinical Laboratory Sciences, 1988, 26, 97-152.	1.0	54
53	Binding of [3H]Monohydroxytamoxifen by Immature Rat Tissues in Vivo*. Endocrinology, 1982, 110, 1281-1291.	2.8	53
54	Modulation of Estrogen Receptor Î± Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12. Journal of Biological Chemistry, 2003, 278, 7630-7638.	3.4	53

#	Article	IF	Citations
55	Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells. Cell Death Discovery, 2018, 4, 15.	4.7	52
56	The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer, 1993, 71, 1501-1505.	4.1	49
57	Ligand Interaction at the Estrogen Receptor to Program Antiestrogen Action: A Study With Nonsteroidal Compoundsin Vitro*. Endocrinology, 1988, 122, 1449-1454.	2.8	48
58	Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Journal of Steroid Biochemistry and Molecular Biology, 2005, 93, 249-256.	2.5	48
59	Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State. Cancer Prevention Research, 2014, 7, 939-949.	1.5	48
60	Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. European Journal of Cancer & Clinical Oncology, 1988, 24, 1817-1821.	0.7	47
61	The Past, Present, and Future of Selective Estrogen Receptor Modulation. Annals of the New York Academy of Sciences, 2001, 949, 72-79.	3.8	47
62	A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. European Journal of Cancer, 2014, 50, 2866-2876.	2.8	46
63	Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. European Journal of Cancer, 2014, 50, 457-468.	2.8	45
64	Molecular Modulation of Estrogen-Induced Apoptosis by Synthetic Progestins in Hormone Replacement Therapy: An Insight into the Women's Health Initiative Study. Cancer Research, 2014, 74, 7060-7068.	0.9	44
65	Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. European Journal of Cancer & Clinical Oncology, 1989, 25, 1777-1788.	0.7	43
66	What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Research and Treatment, 1994, 31, 27-39.	2.5	43
67	Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. Breast Cancer Research and Treatment, 2014, 143, 113-124.	2.5	42
68	Optimising endocrine approaches for the chemoprevention of breast cancer. European Journal of Cancer, 2006, 42, 2909-2913.	2.8	40
69	Structureâ^'Function Relationships of Estrogenic Triphenylethylenes Related to Endoxifen and 4-Hydroxytamoxifen. Journal of Medicinal Chemistry, 2010, 53, 3273-3283.	6.4	40
70	Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors. European Journal of Cancer, 2010, 46, 1537-1553.	2.8	40
71	Tamoxifen: a personal retrospective. Lancet Oncology, The, 2000, 1, 43-49.	10.7	39
72	Regulation of Prolactin Synthesis in Vitro by Estrogenic and Antiestrogenic Derivatives of Estradiol and Estrone*. Endocrinology, 1989, 124, 1717-1726.	2.8	38

#	Article	IF	Citations
73	Long-term adjuvant tamoxifen study: Clinical update. Breast Cancer Research and Treatment, 1987, 9, 157-158.	2.5	37
74	Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. European Journal of Cancer, 2012, 48, 3488-3498.	2.8	37
75	Interaction of [3H] estradiol â€" and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody. Breast Cancer Research and Treatment, 1983, 3, 267-277.	2.5	36
76	The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: Possible role in antiestrogen failure. European Journal of Cancer & Clinical Oncology, 1989, 25, 493-497.	0.7	35
77	Estrogen Receptor Mutations Found in Breast Cancer Metastases Integrated With the Molecular Pharmacology of Selective ER Modulators. Journal of the National Cancer Institute, 2015, 107, djv075.	6.3	35
78	Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. European Journal of Cancer & Clinical Oncology, 1989, 25, 1769-1776.	0.7	34
79	Development and Therapeutic Options for the Treatment of Raloxifene-Stimulated Breast Cancer in Athymic Mice. Clinical Cancer Research, 2006, 12, 2255-2263.	7.0	34
80	Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause, 2013, 20, 372-382.	2.0	34
81	Linking Estrogen-Induced Apoptosis With Decreases in Mortality Following Long-term Adjuvant Tamoxifen Therapy. Journal of the National Cancer Institute, 2014, 106, dju296-dju296.	6.3	34
82	New insights into acquired endocrine resistance of breast cancer. , 2019, 2, 198-209.		32
83	Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells. International Journal of Oncology, 2014, 44, 1529-1538.	3.3	31
84	Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. Steroids, 2014, 90, 44-52.	1.8	30
85	Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement. Breast Cancer Research and Treatment, 2015, 150, 265-278.	2.5	30
86	Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different <scp>CYP2D</scp>6 genotypes. British Journal of Pharmacology, 2014, 171, 5624-5635.	5.4	29
87	Proteomic Analysis of Pathways Involved in Estrogen-Induced Growth and Apoptosis of Breast Cancer Cells. PLoS ONE, 2011, 6, e20410.	2.5	28
88	TAMOXIFEN AND ENDOMETRIAL CANCER. Lancet, The, 1988, 332, 1019.	13.7	27
89	The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Molecular and Cellular Endocrinology, 2015, 418, 245-263.	3.2	27
90	Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells. Molecular Cancer Research, 2015, 13, 1367-1376.	3.4	26

#	Article	IF	Citations
91	Obesity and male breast cancer: provocative parallels?. BMC Medicine, 2015, 13, 134.	5.5	26
92	Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Research, 2003, 63, 7490-6.	0.9	26
93	50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?. Endocrine-Related Cancer, 2021, 28, R11-R30.	3.1	25
94	Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clinical Cancer Research, 2002, 8, 1995-2001.	7.0	25
95	Defining the Conformation of the Estrogen Receptor Complex That Controls Estrogen-Induced Apoptosis in Breast Cancer. Molecular Pharmacology, 2014, 85, 789-799.	2.3	24
96	Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer. JAMA Oncology, 2018, 4, 15.	7.1	24
97	Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Molecular Pharmacology, 2018, 94, 812-822.	2.3	24
98	Preclinical studies with toremifene as an antitumor agent. Breast Cancer Research and Treatment, 1990, 16, S-S.	2.5	22
99	The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. Steroids, 2014, 90, 3-12.	1.8	22
100	Targeting Peroxisome Proliferator-Activated Receptor Î³ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells. Molecular Cancer Therapeutics, 2018, 17, 2732-2745.	4.1	22
101	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. Endocrine-Related Cancer, 2018, 25, R83-R113.	3.1	21
102	Molecular Mechanism of Action at Estrogen Receptor Â of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen. Endocrinology, 2001, 142, 838-846.	2.8	21
103	A Retrospective: On Clinical Studies with 5-Fluorouracil. Cancer Research, 2016, 76, 767-768.	0.9	20
104	Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 33-39.	2.5	19
105	Avoiding the Bad and Enhancing the Good of Soy Supplements in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, dju233-dju233.	6.3	19
106	Suppression of Nuclear Factor-Î°B by Glucocorticoid Receptor Blocks Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells. Molecular Cancer Therapeutics, 2019, 18, 1684-1695.	4.1	19
107	The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Molecular Pharmacology, 2020, 98, 24-37.	2.3	19
108	Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: A unifying concept in anti-hormone resistance. International Journal of Oncology, 2010, 37, 387-98.	3.3	18

#	Article	IF	Citations
109	Influence of the Length and Positioning of the Antiestrogenic Side Chain of Endoxifen and 4-Hydroxytamoxifen on Gene Activation and Growth of Estrogen Receptor Positive Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 4569-4583.	6.4	18
110	Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. International Journal of Oncology, 2007, 30, 509-20.	3.3	18
111	The conformation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: a hypothesis. Hormone Molecular Biology and Clinical Investigation, 2011, 5, 27-34.	0.7	17
112	Pharmacological Relevance of Endoxifen in a Laboratory Simulation of Breast Cancer in Postmenopausal Patients. Journal of the National Cancer Institute, 2014, 106, .	6.3	17
113	Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 2515-2526.	4.1	17
114	Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Womenâ€™s Health. Endocrinology, 2018, 159, 2980-2990.	2.8	17
115	Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. Journal of Clinical Oncology, 2019, 37, 1982-1983.	1.6	17
116	Molecular Mechanism for Breast Cancer Incidence in the Women's Health Initiative. Cancer Prevention Research, 2020, 13, 807-816.	1.5	17
117	Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Pharmacology, 2020, 98, 364-381.	2.3	17
118	Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer. Discovery Medicine, 2016, 21, 411-27.	0.5	16
119	TAMOXIFEN AND ENDOMETRIAL CANCER. Lancet, The, 1989, 333, 733-734.	13.7	15
120	Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. European Journal of Cancer, 2014, 50, 2877-2886.	2.8	15
121	Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2Î±) Protein. Molecular Cancer Research, 2019, 17, 918-928.	3.4	15
122	An appraisal of strategies to reduce the incidence of breast cancer. Stem Cells, 1993, 11, 252-262.	3.2	14
123	Estrogen-Mediated Mechanisms to Control the Growth and Apoptosis of Breast Cancer Cells. Vitamins and Hormones, 2013, 93, 1-49.	1.7	13
124	Questions about Tamoxifen and the Future Use of Antiestrogens. Oncologist, 1998, 3, 104-110.	3.7	13
125	Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. Oncotarget, 2016, 7, 71235-71254.	1.8	13
126	PERK, Beyond an Unfolded Protein Response Sensor in Estrogen-Induced Apoptosis in Endocrine-Resistant Breast Cancer. Molecular Cancer Research, 2022, 20, 193-201.	3.4	13

#	Article	IF	Citations
127	Re: Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17beta-Estradiol and The Two Faces of Janus: Sex Steroids as Mediators of Both Cell Proliferation and Cell Death. Journal of the National Cancer Institute, 2002, 94, 1173-1173.	6.3	11
128	Selective estrogen-induced apoptosis in breast cancer. Steroids, 2014, 90, 60-70.	1.8	11
129	Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale. British Journal of Clinical Pharmacology, 2015, 79, 254-267.	2.4	11
130	How PERK kinase conveys stress signals to nuclear factor-Î¹B to mediate estrogen-induced apoptosis in breast cancer cells?. Cell Death and Disease, 2018, 9, 842.	6.3	11
131	The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture. Annals of Surgical Oncology, 2019, 26, 1981-1990.	1.5	11
132	Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2021, 20, 11-25.	4.1	11
133	A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis?. Menopause, 2014, 21, 1160-1164.	2.0	10
134	The modulation of estrogen-induced apoptosis as an interpretation of the womenâ€™s health initiative trials. Expert Review of Endocrinology and Metabolism, 2016, 11, 81-86.	2.4	10
135	Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen. Breast Cancer, 1998, 5, 99-106.	2.9	9
136	Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. Clinical Cancer Research, 2018, 24, 3480-3482.	7.0	8
137	Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer. Targeted Oncology, 2022, 17, 111-124.	3.6	7
138	Binding of [3H] monohydroxytamoxifen in ovarian carcinoma. BJOG: an International Journal of Obstetrics and Gynaecology, 1983, 90, 751-758.	2.3	6
139	Surgical Oncology Forum: Tamoxifen for the Prevention of Breast Cancer in the High-Risk Woman. Annals of Surgical Oncology, 2000, 7, 67-71.	1.5	6
140	Tamoxifen-Failed Male Breast Cancer with a High Level of Circulating Estrogen: Report of a Case. Surgery Today, 2001, 31, 149-151.	1.5	6
141	Chemoprevention with Antiestrogens: The Beginning of the End for Breast Cancer. Annals of the New York Academy of Sciences, 2001, 952, 60-72.	3.8	6
142	Angela M. Hartley Brodie (1934â€“2017). Nature, 2017, 548, 32-32.	27.8	6
143	Endoxifen: The End, or Are We at the Beginning?. Journal of Clinical Oncology, 2017, 35, 3378-3379.	1.6	6
144	Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. Breast Cancer Research and Treatment, 2021, 190, 19-38.	2.5	6

#	Article	IF	Citations
145	Estrogen Action, Selective Estrogen Receptor Modulators and Women's Health. , 2013, , .		6
146	Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy. Breast Cancer, 1998, 5, 211-217.	2.9	5
147	A Novel Strategy to Improve Womenâ€™s Health: Selective Estrogen Receptor Modulators. Cancer Drug Discovery and Development, 2019, , 189-213.	0.4	5
148	Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.. Journal of Clinical Oncology, 2015, 33, 1500-1500.	1.6	5
149	Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer. JAMA Oncology, 2017, 3, 163.	7.1	4
150	Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERÎ±-positive breast cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 355-371.	0.8	4
151	Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. International Journal of Oncology, 2010, 36, 451-8.	3.9	4
152	Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective. Oncology, 2006, 20, 553-62; discussion 567-8, 573, 577.	0.5	4
153	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. Expert Review of Anticancer Therapy, 2017, 17, 297-310.	2.4	3
154	The Study of Letrozole Extension (SOLE) revisited. Lancet Oncology, The, 2018, 19, e77.	10.7	3
155	Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer. Frontiers in Endocrinology, 2022, 13, 869562.	3.5	3
156	Design of an ideal hormone replacement therapy for women. Molecular Carcinogenesis, 1996, 17, 108-111.	2.7	2
157	Introduction to a special edition in Steroids of nuclear hormone receptor modulators. Steroids, 2014, 90, 1-2.	1.8	2
158	The 4Ps of Breast Cancer Chemoprevention: Putting Proven Principles into Practice. Cancer Prevention Research, 2017, 10, 219-222.	1.5	2
159	Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer. JAMA Oncology, 2017, 3, 1141.	7.1	2
160	Steroid Receptors in Breast Cancer. , 2018, , 272-281.e2.		2
161	Moving Precision Oncology Forward Amid Myths and Misconceptions. JAMA Oncology, 2018, 4, 1789.	7.1	2
162	Estrogen for the Treatment and Prevention of Breast Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 163-168.	2.0	2

#	Article	IF	Citations
163	Introducing a new section to Breast Cancer Research: Endocrinology and hormone therapy. Breast Cancer Research, 2003, 5, 281-3.	5.0	1
164	Estrogen Activity in Plastic Products: Yang et al. Respond. Environmental Health Perspectives, 2011, 119, .	6.0	1
165	Progesterone and Synthetic Progestin Controversies. JAMA Oncology, 2015, 1, 986.	7.1	1
166	A Raloxifene Withdrawal Response. Integrative Cancer Therapies, 2016, 15, 242-244.	2.0	1
167	Differing Perspectives on Breast Cancer Chemoprevention. JAMA Oncology, 2016, 2, 276.	7.1	1
168	Tamoxifen Decreases Mortality, but How?. Journal of Clinical Oncology, 2017, 35, 379-379.	1.6	1
169	A life in breast cancer research: tamoxifen, SERMs and the unique paired-biology of the unfolded protein response and apoptosis. Breast Cancer Management, 2019, 8, BMT21.	0.2	1
170	The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale. Cancer Drug Discovery and Development, 2019, , 151-188.	0.4	1
171	Optimisation of antioestrogen therapy: laboratory and clinical concepts. Proceedings of the Royal Society of Edinburgh Section B Biological Sciences, 1989, 95, 239-246.	0.2	0
172	Toremifene as an Anticancer Agent. Cancer Investigation, 1990, 8, 271-272.	1.3	0
173	Changes in lipid metabolism by tamoxifen. International Journal of Clinical Oncology, 1999, 4, 121-122.	2.2	0
174	New strategies for the treatment of breast cancer. Breast Cancer, 2001, 8, 265-274.	2.9	0
175	Adapting to change and seeing the opportunities in breast cancer management. Breast Cancer Management, 2012, 1, 1-3.	0.2	0
176	Tamoxifen, raloxifene and selective estrogen receptor modulators to estrogen-induced apoptosis, one thing led to another. Breast Cancer Management, 2015, 4, 289-293.	0.2	0
177	Cancer chemoprevention at the crossroads?. Breast Cancer Management, 2015, 4, 285-288.	0.2	0
178	Oral pure antiestrogens as a solution to acquired drug resistance to aromatase inhibitors. Breast Cancer Management, 2015, 4, 275-277.	0.2	0
179	Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity. Journal of Clinical Oncology, 2016, 34, 2675-2676.	1.6	0
180	ASO Author Reflections: An Optimal Biological Model for Successful Drug Discovery. Annals of Surgical Oncology, 2019, 26, 1991-1992.	1.5	0

#	Article	IF	Citations
181	Is There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer?. , 2016, , 83-101.		0
182	Serendipity in the search for â€œmorning-after pillsâ€•led to clomiphene for the induction of ovulation. F&S Science, 2020, 1, 3-13.	0.9	0
183	â€œIf I wanted to buy your brain, what would that cost?â€• rebirth at M.D. Anderson Cancer Center. , 2022, , 187-194.		0
184	An account of students obtaining a Ph.D. degree (or an MD for physicians in the British System) while inÂthe Tamoxifen Team over the last 50 years. , 2022, , 207-220.		0
185	Get out and go to Georgetown. , 2022, , 163-169.		0
186	Closing the circle on Tamoxifen Tales. , 2022, , 171-186.		0